

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. **(Previously Presented)** A method for eliminating a target cell or antigen from the circulatory system of a subject comprising, administering to the subject a composition comprising monomeric IgA that binds to Fc α RI and an agent which specifically binds to the target cell or antigen.
- 2-5. **(Canceled)**
6. **(Previously Presented)** The method of claim 1, wherein the agent comprises an antibody or an antibody fragment thereof.
7. **(Original)** The method of claim 1, wherein the target cell is a cancer cell.
8. **(Original)** The method of claim 1, wherein the target antigen is selected from the group consisting of a bacteria, a virus, and a fungus.
9. **(Original)** The method of claim 1, further comprising the step of administering to the subject a cytokine which increases expression of Fc α RI on Kupffer cells.
10. **(Original)** The method of claim 9, wherein the cytokine is selected from the group consisting of GM-CSF, IL-6, IL-1 β , IL-8, and TNF- α .
11. **(Previously Presented)** The method of claim 1, wherein the composition is administered by injection.

12. **(Previously Presented)** The method of claim 11, wherein the composition is administered intravenously.

13-34. **(Canceled)**

35. **(New)** A method for eliminating a target cell or antigen from the circulatory system of a subject comprising, administering to the subject a composition comprising monomeric IgA.

36. **(New)** The method of claim 35, wherein the target cell is a cancer cell.

37. **(New)** The method of claim 35, wherein the target antigen is selected from the group consisting of a bacteria, a virus, and a fungus.

38. **(New)** The method of claim 35, further comprising the step of administering to the subject a cytokine which increases expression of Fc α RI on Kupffer cells.

39. **(New)** The method of claim 38, wherein the cytokine is selected from the group consisting of GM-CSF, IL-6, IL-1 β , IL-8, and TNF- α .

40. **(New)** The method of claim 35, wherein the composition is administered by injection.

41. **(New)** The method of claim 35, wherein the composition is administered intravenously.